North American Report

Acral Lentiginous Melanoma Market Size: Industry Analysis, Key Companies, Emerging Drugs, Trends, Growth and Epidemiology Forecast by DelveInsight

 Breaking News
  • No posts were found

Acral Lentiginous Melanoma Market Size: Industry Analysis, Key Companies, Emerging Drugs, Trends, Growth and Epidemiology Forecast by DelveInsight

April 12
18:31 2021
Acral Lentiginous Melanoma Market Size: Industry Analysis, Key Companies, Emerging Drugs, Trends, Growth and Epidemiology Forecast by DelveInsight

Acral Lentiginous Melanoma Market
According to AIM at Melanoma Foundation, Acral Lentiginous Melanoma (ALM) is a type of melanoma that appears on the palms of the hands, the soles of the feet, or under the nails. ALM starts as a slowly-enlarging flat patch of discolored skin. At first, the malignant cells remain within the epidermis—the in situ phase of melanoma, which can persist for months or years.

DelveInsight’s “Acral Lentiginous Melanoma Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Acral Lentiginous Melanoma, historical and forecasted epidemiology as well as the Acral Lentiginous Melanoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Acral Lentiginous Melanoma market report also covers emerging drugs, current treatment practices, Acral Lentiginous Melanoma market size and share of the individual therapies, current and forecasted Acral Lentiginous Melanoma Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Acral Lentiginous Melanoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

 

Acral Lentiginous Melanoma Market Key Facts

  • According to the study by Ciocan et al. titled “Distinctive Features of Melanoma and Its Management in Elderly Patients A Population-Based Study in France,” older patients developed nodular melanoma, lentigo maligna melanoma, or acral lentiginous melanoma more frequently.
  • According to the article by Kai et al., titled “Management of Acral Lentiginous Melanoma,” the incidence of ALM in the US is approximately 2‒3%.
  • The study by Bradford et al. also revealed that approximately 37.8% of ALMs were in stage I. In men, 30.0% of ALM cases diagnosed were at stage I as compared to 41.9% in women. The highest percentage of ALM cases diagnosed at stage I and III were found in non-Hispanic whites (40.1%) and Asian/Pacific Islanders (50%), respectively.
  • The proportions of ALM in all CM were reported to be 3.8% in Germany, and 47% in Japan, which lead to the estimated incidence rates of people with ALM of 0.73 per 100,000 per year in Germany and 0.71 patients per 100,000 per year in Japan.

 

Get FREE sample copy at:
https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-market

 

Key Benefits of Acral Lentiginous Melanoma Market Report

  • Acral Lentiginous Melanoma market report provides an in-depth analysis of Acral Lentiginous Melanoma Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
  • The Acral Lentiginous Melanoma market report will help in developing business strategies by understanding the Acral Lentiginous Melanoma Market trends & developments, key players, and future market competition that will shape and drive the Acral Lentiginous Melanoma market in the upcoming years.
  • The Acral Lentiginous Melanoma market report covers Acral Lentiginous Melanoma market growth and current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
  • The report provides a detailed assessment of the Acral Lentiginous Melanoma patient population, market drivers & barriers, Unmet Needs, market opportunities, comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

 

Acral Lentiginous Melanoma Market

As per the DelveInsight, the rise in the incidence of Acral Lentiginous Melanoma will boost the market growth during the forecasted period.

The Acral Lentiginous Melanoma market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Acral Lentiginous Melanoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology. 

The report gives a thorough detail of Acral Lentiginous Melanoma market trends and shares analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

 

Get FREE sample copy at:
https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-market

 

Acral Lentiginous Melanoma Drugs Uptake and Key Market Players

The Acral Lentiginous Melanoma Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acral Lentiginous Melanoma market or expected to get launched in the market during the study period. The analysis covers Acral Lentiginous Melanoma market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The current clinical pipeline of Acral Lentiginous Melanoma is weak. However, some of the key players are working toward the development of therapies for Acral Lentiginous Melanoma which includes

  • Atreca
  • Bristol-Myers Squibb.
  • And Many Others

 

Acral Lentiginous Melanoma Therapies Covered in the report include:
ATRC-101
Nivolumab with Ipilimumab
And many others.

 

Get FREE sample copy at:
https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-market

 

Table of Content

  1. Key Insights
  2. Executive Summary 
  3. Acral Lentiginous Melanoma Competitive Intelligence Analysis
  4. Acral Lentiginous Melanoma Market Overview at a Glance
  5. Acral Lentiginous Melanoma Disease Background and Overview
  6. Acral Lentiginous Melanoma Patient Journey
  7. Acral Lentiginous Melanoma Epidemiology and Patient Population
  8. Acral Lentiginous Melanoma Treatment Algorithm, Current Treatment, and Medical Practices
  9. Acral Lentiginous Melanoma Unmet Needs
  10. Key Endpoints of Acral Lentiginous Melanoma Treatment
  11. Acral Lentiginous Melanoma Marketed Products
  12. Acral Lentiginous Melanoma Emerging Therapies
  13. Acral Lentiginous Melanoma Seven Major Market Analysis
  14. Attribute Analysis
  15. Acral Lentiginous Melanoma Market Outlook (7 major markets)
  16. Acral Lentiginous Melanoma Access and Reimbursement Overview
  17. KOL Views on the Acral Lentiginous Melanoma Market.
  18. Acral Lentiginous Melanoma Market Drivers
  19. Acral Lentiginous Melanoma Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-market

Categories